JHS Svendgaard Laboratories Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 2.5 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JHS Svendgaard Laboratories reported audited financial results for FY26 with revenue from operations growing 10.5% to Rs 10,169.47 lakhs from Rs 9,199.73 lakhs in FY25. The company significantly narrowed its net loss to Rs 191.73 lakhs compared to a loss of Rs 1,973.84 lakhs in the previous year. The Q4 standalone loss was Rs 356.56 lakhs, improved from Rs 695.67 lakhs in Q4 FY25. The auditor issued an unmodified (clean) opinion. An emphasis of matter was raised regarding capital advances of Rs 4,190.82 lakhs (net of provision) for manufacturing facilities in Himachal Pradesh and a project in Jammu & Kashmir, though management considers these recoverable. The company also needs to strengthen internal financial controls over trade receivables, payables, and inventory management. No dividend was declared.
While the company shows improving operational performance with narrowed losses, it remains unprofitable for the year. The clean audit opinion and adequate going concern assessment are positive, but investors should monitor the recoverability of capital advances and the strengthening of internal controls flagged by the auditor.